Atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: A 6-week, randomized, placebo-controlled, double-blind trial in Russia

European Child and Adolescent Psychiatry

Volumn 19, Issue 1, 2010, Pages 57-66

  Martenyi, Ferenc ^a   Zavadenko, Nikolay N ^b   Jarkova, Natalia B ^c   Yarosh, Alexandr A ^d   Soldatenkova, Victoria O ^d   Bardenstein, Leonid M ^b   Kozlova, Irina A ^e   Neznanov, Nikolay G ^f   Maslova, Olga I ^g   Petrukhin, Andrey S ^b   Sukchotina, Nina K ^h   Zykov, Valeriy P ⁱ  

^a ELI LILLY AND COMPANY   (United States)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^c Eli Lilly   (Russian Federation)

^d InnoPharm Ltd   (Russian Federation)

^e MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^f Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

^g INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^h Scientific and Research Institute of Psychiatry   (Russian Federation)

ⁱ Russian Medical Academy of Postgraduate Education   (Russian Federation)

Author keywords

ADHD; Atomoxetine; Children; Nonstimulant; Once daily

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; MALE; NAUSEA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RUSSIAN FEDERATION; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION;

ABDOMINAL PAIN; ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ANALYSIS OF VARIANCE; ANOREXIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NAUSEA; PARENTS; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; RUSSIA; SLEEP; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 73449130156     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-009-0042-7     Document Type: Article

References (31)

1. RA Altschuler MD Maschkovsky LF Roshchina 1973 Sydnocarb is a new stimulant of the central nervous system Farmacol Toxicol 36 18 23 (in Russian)
2. RA Barkley MB Murrary CS Edelbrock K Robbins 1990 Side effects of methylphenidate in children with attention-deficit hyperactivity disorder: a systemic, placebo-controlled evaluation Pediatrics 86 184 192 1:STN:280:DyaK3czhvVOquw%3D%3D 2196520
3. V Bashkatova AM Mathieu-Kia C Durand J Penit-Soria 2002 Neurochemical changes and neurotoxic effects of an acute treatment with sydnocarb, a novel psychostimulant: comparison with D-amphetamine Ann N Y Acad Sci 965 180 192 1:CAS:528:DC%2BD38XlvVOjt78%3D 12105094
4. SA Borinskaya ZhM Kozhekbaeva EV Gorbunova, et al. 2004 Analysis of the DRD4 gene polymorphism in populations of Russia and neighboring countries Russ J Genet 40 679 683 10.1023/B:RUGE.0000033316.17087.62 1:CAS:528: DC%2BD2cXlt1Crtb4%3D (in Russian) (Pubitemid 41071239)
5. CK Conners G Sitarenios JD Parker JN Epstein 1998 The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity J Abnorm Child Psychol 26 257 268 10.1023/A:1022602400621 1:STN:280:DyaK1czmsFyktw%3D%3D 9700518 (Pubitemid 28359774)
6. Crichton A (1798) An Inquiry into the nature and origin of mental derangement: comprehending a concise system of physiology and pathology of the human mind and history of the passions and their effects. T. Cadell Jr. and W Davies, London (Reprinted by AMS Press, New York, 1976)
7. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD rating scale-IV: checklists, norms, and clinical interpretations. The Guilford Press, New York, NY
8. Faraone SV (2003) Understanding the effect size of ADHD medication: implications for clinical care. Medscape Psych Ment Health 28:2. www.medscape.com/viewarticle/461543
9. SV Faraone J Sergeant C Gillberg J Biederman 2003 The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2 104 113 16946911
10. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare, Bethesda, MD
11. Ireland W (1877) On idiocy and imbecility. JSA Churchill, London
12. J Kaufman B Birmaher D Brent, et al. 1997 Schedule for affective disorders and schizophrenia for school-age children present and lifetime version (K-SADS-PL): initial reliability and validity data J Am Acad Child Adolesc Psychiatry 136 980 988
13. DK Kelsey CR Sumner CD Casat, et al. 2004 Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial Pediatrics 114 e1 e8 10.1542/peds.114.1.e1 15231966
14. Kornilova TV, Grigorenko EL, Smirnov SD (2004) Teenagers of risk groups. Piter Publishers, Moscow-Saint Petersburg, pp 161-333
15. VA Krasov 1988 Sydnocarb treatment of young schoolchildren with hyperdynamic syndrome Zh Nevropatol Psikhiatr Im S S Korsakova 88 97 101 1:STN:280:DyaL1M%2FlvFOiuw%3D%3D 3195293 (in Russian)
16. CJ Kratochvil TE Wilens LL Greenhill, et al. 2006 Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 45 919 927 10.1097/01.chi. 0000222788.34229.68 16865034 (Pubitemid 44126866)
17. D Michelson D Faries J Wernike, et al. 2001 Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study Pediatrics 108 E83 10.1542/peds.108.5.e83 1:STN:280:DC%2BD3MnktF2qtw%3D%3D 11694667
18. D Michelson AJ Allen J Busner, et al. 2002 Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 159 1896 1901 10.1176/appi.ajp.159.11.1896 12411225 (Pubitemid 35283256)
19. Newcorn J, Allen AJ, Sutton V et al (2003) Characteristics of placebo responders in pediatric ADHD clinical trials. Paper presented at the 50th annual meeting of the American academy of child and adolescent psychiatry. Miami, FL
20. HJ Newcorn TJ Spencer J Biederman DR Milton D Michelson 2005 Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder J Am Acad Child Adolesc Psychiatry 44 240 248 10.1097/00004583-200503000-00008 15725968 (Pubitemid 40299837)
21. HJ Newcorn CJ Kratochwill AJ Allen, et al. 2008 Atomoxetine and osmotically released methylphenidate for the treatment of attention-deficit hyperactivity disorder: acute comparison and differential response Am J Psychiatry 165 721 730 10.1176/appi.ajp.2007.05091676 18281409 (Pubitemid 351810541)
22. ED Palmer S Finger 2001 An early description of ADHD (inattentive subtype): Dr Alexander Crichton and "mental restlessness" (1798) Child Psychol Psychiatry Review 6 66 73
23. G Polanczyk MS de Lima BL Horta J Biederman LA Rohde 2007 The worldwide prevalence of ADHD: a systematic review and meta-regression analysis Am J Psychiatry 164 942 948 10.1176/appi.ajp.164.6.942 17541055 (Pubitemid 46972911)
24. Still GF (1902) The Culostian lectures on some abnormal psychical conditions in children. Lancet i1008-i1012
25. Tredgold AF (1908) Mental deficiency (amentia). Tindall and Cox, Bailliere
26. US Department of Health and Human Services (1995) COSTART: coding symbols of thesaurus of adverse reaction terms, 5th edn. US Food and Drug Administration, Rockville, MD
27. MG Uzbekov EY Misionzhnik 2003 Changes in urinary monoamine excretion in hyperkinetic children Hum Psychopharmacol 18 493 497 10.1002/hup.513 1:CAS:528:DC%2BD3sXnvVSktLc%3D 12923831 (Pubitemid 37038349)
28. M Weiss R Tannock C Kratochvil, et al. 2005 A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD J Am Acad Child Adolesc Psychiatry 44 647 655 10.1097/01.chi.0000163280.47221.c9 15968233 (Pubitemid 40875359)
29. Zavadenko N, Suvorinova N (1999) ADHD: study of motor control, attention, memory and experience with nootropics. In: Evrard Ph, Richelme Ch, Tardieu M (eds) Proceedings of the 3rd European paediatric neurology (EPNS) congress, Bologna, Monduzzi Editore, pp 81-85
30. NN Zavadenko Uspenskaia TIu Suvorinova NIu 1997 The diagnosis and treatment of the attention-deficit syndrome in children Zh Nevropatol Psikhiatr Im S S Korsakova 97 1 57 61 1:STN:280:DyaK2s3htFGrtg%3D%3D
31. Zavadenko N, Petrukhin A, Suvorinova N, Grigorieva N (1998) ADHD: study of prevalence, aetiology and efficiency of nootropics therapy. In: Velickovic Perat M (ed) New developments in child neurology. Monduzzi Editore, Bologna, pp 675-679